新闻

CMS: Approval Of Drug Clinical Trials For Vitiligo & Hidradenitis Suppurativa Indication Of Innovative Drug Oral Small-Molecule JAK1 Inhibitor Povorcitinib.

29 Aug 2025 09:46

Povorcitinib is a selective oral small-molecule JAK1 inhibitor, with compound and use patents in certain countries/regions in the Territory...

Attachments:

• CMS_-_Ann_-_Approval_of_Clinical_Trials_for_Vitiligo_and_Hidradenitis_28Aug2025.pdf

Source: ShareInvestor Express